Oct 1, 2024 · On June 27, 2024, the Advisory Committee on Immunization Practices recommended 21-valent PCV (PCV21) as an option for adults aged ≥19 years who are currently recommended to receive PCV15 or PCV20. PCV21 contains eight serotypes not included in other licensed vaccines. What are the implications for public health practice?

Oct 26, 2024 · Based on shared clinical decision-making, adults 65 years or older have the option to get PCV20 or PCV21, or to not get additional pneumococcal vaccines. They can get PCV20 or PCV21 if they have received both.

Sep 12, 2024 · CAPVAXIVE TM (PCV21) helps protect against 21 types of pneumococcal bacteria. Vaccine providers may give PPSV23 to children 2 through 18 years old with certain conditions. Vaccine providers give it to adults who receive PCV15. They also may give it to adults who have received an earlier vaccine called PCV13.

Jun 17, 2024 · CAPVAXIVE is Merck’s approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of invasive disease and pneumonia in adults 18 years of age and older.

CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) is indicated for: active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A,

CAPVAXIVE (PCV21) is a 21-valent conjugate pneumococcal vaccine, of purified capsular polysaccharides from 21 serotypes (ST) of Streptococcus pneumoniae, which induces an immune response against those vaccine serotypes, measured as opsonophagocytic activity (OPA).

Jul 17, 2024 · Active immunization for the prevention of pneumonia caused by S. pneumoniaeserotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F,23A, 23B, 24F, 31, 33F, and 35B in...

Find information about CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) to see if the vaccine is right for you.

Mar 1, 2025 · Pneumococcal 21-valent conjugate vaccine is an active immunizing agent used to prevent infection caused by certain types of pneumococcal bacteria (Streptococcus pneumoniae). It works by causing your body to produce its own protection (antibodies) against the disease.

On June 27, 2024, the Advisory Committee on Immunization Practices recommended 21-valent PCV (PCV21) as an option for adults aged ≥19 years who are currently recommended to receive PCV15 or PCV20. PCV21 contains eight serotypes not included in other licensed vaccines.